Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 134 clinical trials
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

major surgery
enzalutamide
luteinising hormone
gonadotropin
corticosteroids
  • 2 views
  • 19 Feb, 2024
  • 16 locations
Interactive Decision Aid for Men Diagnosed With Prostate Cancer

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).

cancer diagnosis
  • 0 views
  • 19 Feb, 2024
  • 1 location
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

MRI
prostate specific antigen
positron emission tomography
fluciclovine (18f)
conventional imaging
  • 0 views
  • 19 Feb, 2024
  • 1 location
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

definitive treatment
testosterone level
local therapy
tumor progression
serum testosterone
  • 0 views
  • 19 Feb, 2024
  • 1 location
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

multiparametric magnetic resonance imaging
pet/ct scan
positron emission tomography
digital rectal examination
  • 0 views
  • 19 Feb, 2024
  • 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.

MRI
gonadotropin
lymphadenectomy
testosterone
immunological adjuvant
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
enzalutamide
taxane
combined modality therapy
antiandrogen therapy
  • 0 views
  • 19 Feb, 2024
  • 22 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

soft tissue disease
metastatic castration-resistant prostate cancer
bone scan
progressive disease
bone lesion
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

ejection fraction
enzalutamide
gonadotropin
blood transfusion
serum testosterone
  • 0 views
  • 19 Feb, 2024
  • 4 locations
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.

prostate specific antigen
positron emission tomography
local therapy
cancer recurrence
lymphadenectomy
  • 0 views
  • 19 Feb, 2024
  • 1 location